Announcements Trials
Browse Landscape

Phase

Phase 2 8Phase 3 4Phase 1/2 3Phase 1 3Phase 2/3 1

Status

Active not recruiting 2Recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 1Breast 1

Conditions

PIK3CA-Mutated Cancers 1Colorectal Neoplasms 1Breast Neoplasms 1

Interventions

Specimen Handling 147pembrolizumab 124Magnetic Resonance Spectroscopy 114Cyclophosphamide 114Biopsy 104fludarabine 84Nivolumab 59Carboplatin 54Gemcitabine 46Cisplatin 46venetoclax 45Radiotherapy 45Paclitaxel 43Ipilimumab 38fludarabine phosphate 37Cetuximab 37Fluorouracil 34atezolizumab 31Bevacizumab 31durvalumab 30X-Rays 28Oxaliplatin 28Dexamethasone 28Leucovorin 27Radiation 26Irinotecan 26Azacitidine 25Injections 24Cytarabine 24Radiosurgery 22

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × inavolisib × 90 days × Clear all
NCT06496568 2026-05-27

A Study Evaluating Single-agent Inavolisib, Inavolisib Plus Atezolizumab in PIK3CA-Mutated Cancers

Hoffmann-La Roche

Phase 1 Active not recruiting
30 enrolled

PIK3CA-Mutated Cancers

NCT04929223 2026-05-26

A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)

Hoffmann-La Roche

Phase 1 Recruiting
542 enrolled
Gastrointestinal

Colorectal Neoplasms

NCT03006172 2026-03-11

To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer

Genentech, Inc.

Phase 1 Active not recruiting
200 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡